Helix BioPharma Corp., an immuno-oncology company in Richmond Hill, Ontario that develops innovative drug candidates for the prevention and treatment of cancer, announces the formation of the Scientific and Strategic Advisory Board (SSAB) with a renowned group of physicians and scientists.
Members of the SSAB include Dr. Daniel Von Hoff, Dr. Kazimierz Roszkowski-Sliz and Dr. Robert Gillies.
Dr. Von Hoff is currently physician in chief and distinguished professor of translational research at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also senior consultant of clinical investigations for the City of Hope; chief scientific officer for HonorHealth Research Institute; medical director of research, chief scientific officer, US Oncology, professor of medicine at Mayo Clinic and past president of the American Association for Cancer Research. Dr. Von Hoff was involved in a development of a number of therapeutics that are routinely used in treating cancer today.
Dr. Roszkowski-Sliz is the director and head of clinical at the National Tuberculosis and Lung Diseases Research Institute in Poland; national consultant for lung diseases, Ministry of Health; chairman of Scientific Council of Ministry of Health; and Chairman of the Scientific Council of the National Center Institute of Oncology, Poland. Dr. Roszkowski-Sliz is an expert in the treatment of lung diseases.
Dr. Robert Gillies holds the Martin Silbiger Endowed Chair and is Chair of the Department of Cancer Physiology and Vice-Chair (Research) of the Department of Radiology, H. Lee Moffitt Cancer Center and Research Institute; and Professor Emeritus, Departments of Radiology and Biomedical Engineering, College of Medicine, University of Arizona. He is past president of the Society for Molecular Imaging and has served on numerous grant review panels for the National Institutes of Health and the U.S. Department of Defense, consulting on cancer physiology and imaging. Dr. Gillies is an expert in tumor acidity and has published extensively in this area of research.
The Company’s SSAB is mandated to provide scientific and strategic advice to Helix. They will regularly be joined by Herman Chao, CEO and CSO, Helix BioPharma.
“We are thrilled to have attracted some of the world’s leading experts in cancer treatment and drug development to Helix’s team,” says Dr. Slawomir Majewski, Chairman of the Board. “Importantly, the formation of our SSAB serves as an endorsement for scientific and clinical enthusiasm for DOS47 and more broadly the Company’s unique tumor microenvironment platform.”